ALK and non-small cell lung carcinoma: The FDA approved crizotinib in 2011 for the treatment of locally advanced or metastatic ALK-positive NSCLC and later in 2016 for ROS1-positive metastatic NSCLC (Malik et al., 2014; Nadal et al., 2024).